Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)

•Radiochemotherapy remains the standard treatment for anal cancer since the ‘90s.•Our results suggest that a longer overall treatment time may be detrimental to outcome.•In the dose range of 50.4–59 Gy, lower doses seem to be preferred.•A longer than 2-week gap might be detrimental.•Findings may guide trials to define optimal overall treatment time and dose level.